<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CENESTIN- estrogens, conjugated synthetic a tablet, film coated </strong><br>Teva Women's Health, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use <span class="Bold">CENESTIN<span class="Sup">®</span></span> safely and effectively.  See full prescribing information for CENESTIN.<br><span class="Bold">CENESTIN<span class="Sup">®</span> (synthetic conjugated estrogens, A) Tablets for oral use</span><br>Initial U.S. Approval: 1999</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: ENDOMETRIAL CANCER, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span> </h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#_5.2.__Malignant">5.2</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#_5.1__Cardiovascular">5.1</a>, <a href="#_5.3__Probable">5.3</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) (<a href="#_5.1__Cardiovascular">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#_5.3__Probable">5.3</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#_5.1__Cardiovascular">5.1</a>, <a href="#_5.3__Probable">5.3</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of DVT, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) (<a href="#_5.1__Cardiovascular">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen plus progestin study reported increased risks of invasive breast cancer (<a href="#_5.2.__Malignant">5.2</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#_5.3__Probable">5.3</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<dl>
<dt> </dt>
<dd>Contraindication (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>)	03/2015</dd>
<dt> </dt>
<dd>Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary angioedema</span> (<a href="#_5.15__Hereditary">5.15</a>)	03/2015</dd>
</dl>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: ENDOMETRIAL CANCER, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span> </h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#_5.2.__Malignant">5.2</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#_5.1__Cardiovascular">5.1</a>, <a href="#_5.3__Probable">5.3</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) (<a href="#_5.1__Cardiovascular">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#_5.3__Probable">5.3</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#_5.1__Cardiovascular">5.1</a>, <a href="#_5.3__Probable">5.3</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of DVT, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) (<a href="#_5.1__Cardiovascular">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen plus progestin study reported increased risks of invasive breast cancer (<a href="#_5.2.__Malignant">5.2</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#_5.3__Probable">5.3</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Cenestin (synthetic conjugated estrogens, A) tablet is a mixture of estrogens indicated for: </p>
<dl>
<dt>•</dt>
<dd>Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> (<span class="Underline"><a href="#ID_c9df6be2-ab66-466d-82a0-5a936064c86c">1.1</a></span>).</dd>
<dt>•</dt>
<dd>Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> (<span class="Underline"><a href="#ID_7dea9cbc-a32a-4c30-8b67-14e986b5a864">1.2</a></span>).</dd>
<dt> </dt>
<dd>Limitation of Use</dd>
<dt> </dt>
<dd>When prescribing solely for the treatment of symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, topical vaginal products should be considered.</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Cenestin 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablets are taken orally, once daily for the Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> (<a href="#_2.1__Treatment">2.1</a>).</dd>
<dt>•</dt>
<dd>Cenestin 0.3 mg tablets are taken orally, once daily for the Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> (<a href="#_2.2__Treatment">2.2</a>).</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>0.3 mg tablet</dd>
<dt>•</dt>
<dd>0.45 mg tablet</dd>
<dt>•</dt>
<dd>0.625 mg tablet</dd>
<dt>•</dt>
<dd>0.9 mg tablet</dd>
<dt>•</dt>
<dd>1.25 mg tablet</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>)</dd>
<dt>•</dt>
<dd>Known, suspected, or history of cancer of the breast (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>, <a href="#_5.2.__Malignant">5.2</a>)</dd>
<dt>•</dt>
<dd>Known or suspected estrogen-dependent neoplasia (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>, <a href="#_5.2.__Malignant">5.2</a>)</dd>
<dt>•</dt>
<dd>Active DVT, PE, or a history of these conditions (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>, <a href="#_5.1__Cardiovascular">5.1</a>)</dd>
<dt>•</dt>
<dd>Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI), or a history of these conditions (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>, <a href="#_5.1__Cardiovascular">5.1</a>)</dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with Cenestin (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>)</dd>
<dt>•</dt>
<dd>Known liver impairment or disease (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>, <a href="#_5.10__Hepatic">5.10</a>)</dd>
<dt>•</dt>
<dd>Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>)</dd>
<dt>•</dt>
<dd>Known or suspected pregnancy (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>, <a href="#_8.1.__Pregnancy">8.1</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Estrogens increase the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> (<a href="#_5.4__Gallbladder">5.4</a>)</dd>
<dt>•</dt>
<dd>Discontinue estrogen if severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> or <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> occurs (<a href="#_5.5__Hypercalcemia">5.5</a>, <a href="#_5.6__Visual">5.6</a>, <a href="#_5.9__Hypertriglyceridemia">5.9</a>, <a href="#_5.10__Hepatic">5.10</a>)</dd>
<dt>•</dt>
<dd>Monitor thyroid function in women on thyroid replacement therapy (<a href="#_5.11__Hypothyroidism">5.11</a>, <a href="#_5.18__Drug/Laboratory">5.18</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (&gt; 10%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, endometrial thickening, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (<a href="#_6.1__Clinical">6.1</a>). </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Inducers or inhibitors of cytochrome P450 3A4 (CYP3A4) may affect estrogen drug metabolism (<a href="#_7.1__Metabolic">7.1</a>)</dd>
</dl></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing Mothers: Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of breast milk (<a href="#_8.3.__Nursing">8.3</a>)</dd>
<dt>•</dt>
<dd>Geriatric use: An increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women over 65 years of age was reported in the Women’s Health Initiative Memory ancillary studies of the Women’s Health Initiative (<a href="#_5.3__Probable">5.3</a>, <a href="#_8.5.__Geriatric">8.5</a>)<br>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISODERS, BREAST CANCER AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span> </a></h1>
<h1><a href="#section-1" class="toc">INDICATIONS AND USAGE </a></h1>
<h2><a href="#section-1.2" class="toc">1.2  Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> </a></h2>
<h1><a href="#section-2" class="toc">DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> </a></h2>
<h2><a href="#section-2.2" class="toc">2.2  Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> </a></h2>
<h1><a href="#section-3" class="toc">DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS </a></h1>
<h2><a href="#section-5.1" class="toc">5.1  <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Malignant Neoplasms </a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4  <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span> </a></h2>
<h2><a href="#section-5.5" class="toc">5.5  <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> </a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Visual Abnormalities </a></h2>
<h2><a href="#section-5.7" class="toc">5.7  Addition of a Progestin when a Woman has not had a Hysterectomy </a></h2>
<h2><a href="#section-5.8" class="toc">5.8  Elevated Blood Pressure </a></h2>
<h2><a href="#section-5.9" class="toc">5.9  <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> </a></h2>
<h2><a href="#section-5.10" class="toc">5.10  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span> </a></h2>
<h2><a href="#section-5.11" class="toc">5.11  <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> </a></h2>
<h2><a href="#section-5.12" class="toc">5.12  <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> </a></h2>
<h2><a href="#section-5.13" class="toc">5.13  <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> </a></h2>
<h2><a href="#section-5.14" class="toc">5.14  Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> </a></h2>
<h2><a href="#section-5.15" class="toc">5.15  <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span> </a></h2>
<h2><a href="#section-5.16" class="toc">5.16  Exacerbation of Other Conditions </a></h2>
<h2><a href="#section-5.17" class="toc">5.17  Laboratory Tests </a></h2>
<h2><a href="#section-5.18" class="toc">5.18  Drug/Laboratory Test Interactions </a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS </a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Post Marketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc">7.1  Metabolic Interactions </a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.3  Nursing Mothers </a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use </a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use </a></h2>
<h2><a href="#section-8.5" class="toc">8.6  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h2><a href="#section-8.6" class="toc">8.7  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE </a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION </a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY </a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action </a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics </a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics </a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY </a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES </a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Effects on Vasomotor Symptoms </a></h2>
<h2><a href="#section-13.2" class="toc">14.2  Effects on Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> </a></h2>
<h2><a href="#section-13.3" class="toc">14.3  Women’s Health Initiative Studies </a></h2>
<h2><a href="#section-13.4" class="toc">14.4  Women’s Health Initiative Memory Study </a></h2>
<h1><a href="#section-14" class="toc">15  REFERENCES </a></h1>
<h1><a href="#section-15" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h2><a href="#section-15.1" class="toc">16.1  How Supplied </a></h2>
<h2><a href="#section-15.2" class="toc">16.2  Storage and Handling </a></h2>
<h1><a href="#section-16" class="toc">17  PATIENT COUNSELING INFORMATION </a></h1>
<h2><a href="#section-16.1" class="toc">17.1  <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span> </a></h2>
<h2><a href="#section-16.2" class="toc">17.2  Possible Serious Adverse Reactions with Estrogen-Alone Therapy </a></h2>
<h2><a href="#section-16.3" class="toc">17.3  Possible Less Serious but More Common Adverse Reactions with Estrogen-Alone Therapy </a></h2>
<h2><a href="#section-18.1" class="toc">Cenestin® (synthetic conjugated estrogens, A) Tablets 0.3 mg, 100s Label Text </a></h2>
<h2><a href="#section-19.1" class="toc">Cenestin® (synthetic conjugated estrogens, A) Tablets 0.45 mg, 100s Label Text </a></h2>
<h2><a href="#section-20.1" class="toc">Cenestin® (synthetic conjugated estrogens, A) Tablets 0.625 mg, 100s Label Text </a></h2>
<h2><a href="#section-21.1" class="toc">Cenestin® (synthetic conjugated estrogens, A) Tablets 0.9 mg, 100s Label Text </a></h2>
<h2><a href="#section-22.1" class="toc">Cenestin® (synthetic conjugated estrogens, A) Tablets 1.25 mg, 100s Label Text </a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_56a2fd43-ba86-4ae6-8749-dc0de51c338a"></a><a name="section-1"></a><p></p>
<h1>WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISODERS, BREAST CANCER AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span> </h1>
<p class="First"><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span></p>
<p><span class="Bold">Endometrial Cancer</span></p>
<p><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#_5.2.__Malignant">5.2</a>)]</span>.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span></span></p>
<p><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see Warnings and Precautions (<a href="#_5.1__Cardiovascular">5.1</a>, <a href="#_5.3__Probable">5.3</a>), and Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>, <a href="#_14.4__Women%E2%80%99s">14.4</a>)]</span>.</span></p>
<p><span class="Bold">The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo <span class="Italics">[see Warnings and Precautions (<a href="#_5.1__Cardiovascular">5.1</a>), and Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>.</span></p>
<p><span class="Bold">The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#_5.3__Probable">5.3</a>), Use in Specific Populations (<a href="#_8.5.__Geriatric">8.5</a>), and Clinical Studies (<a href="#_14.4__Women%E2%80%99s">14.4</a>)]</span>.</span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.</span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
<p><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></p>
<p><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see Warnings and Precautions (<a href="#_5.1__Cardiovascular">5.1</a>, <a href="#_5.3__Probable">5.3</a>), and Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>, <a href="#_14.4__Women%E2%80%99s">14.4</a>)]</span>.</span></p>
<p><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of DVT, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo <span class="Italics">[see Warnings and Precautions (<a href="#_5.1__Cardiovascular">5.1</a>), and Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>.</span></p>
<p><span class="Bold">The WHIMS estrogen plus progestin ancillary study of the WHI, reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#_5.3__Probable">5.3</a>), Use in Specific Populations (<a href="#_8.5.__Geriatric">8.5</a>), and Clinical Studies (<a href="#_14.4__Women%E2%80%99s">14.4</a>)]</span>.</span></p>
<p><span class="Bold">Breast Cancer</span></p>
<p><span class="Bold">The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer <span class="Italics">[see Warnings and Precautions (<a href="#_5.2.__Malignant">5.2</a>), and Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>.</span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins. </span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_22b2f443-955b-46ee-88ad-dacd0c0b31da"></a><a name="section-1"></a><p></p>
<h1>INDICATIONS AND USAGE </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c9df6be2-ab66-466d-82a0-5a936064c86c"></a><a name="section-1.1"></a><p></p>
<h2>1.1  Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> </h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7dea9cbc-a32a-4c30-8b67-14e986b5a864"></a><a name="section-1.2"></a><p></p>
<h2>1.2  Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> </h2>
<p class="First"><span class="Bold">Limitation of Use</span></p>
<p>When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span><br>due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, topical vaginal products should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_d85b8fae-9e94-457a-b0ea-dec959f304d3"></a><a name="section-2"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION </h1>
<p class="First">Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. </p>
<p>A woman without a uterus does not need progestin. In some cases, however, hysterectomized women with a history of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> may need a progestin <span class="Italics">[see Warnings and Precautions (<a href="#_5.2.__Malignant">5.2</a>, <a href="#_5.14__Exacerbation">5.14</a>)]</span>.</p>
<p>Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4b399ce3-7574-458c-b872-7b98ac8847a6"></a><a name="section-2.1"></a><p></p>
<h2>2.1  Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> </h2>
<p class="First">Cenestin therapy consists of a single tablet taken orally once daily. </p>
<dl>
<dt>•</dt>
<dd>Cenestin 0.45 mg </dd>
<dt>•</dt>
<dd>Cenestin 0.625 mg </dd>
<dt>•</dt>
<dd>Cenestin 0.9 mg </dd>
<dt>•</dt>
<dd>Cenestin 1.25 mg </dd>
</dl>
<p>Patients should be started at Cenestin 0.45 mg daily. Subsequent dosage adjustment may be made based upon the individual patient response. This dose should be periodically reassessed by the healthcare provider. The lowest effective dose of Cenestin for the treatment of moderate to severe vasomotor symptoms has not been determined.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fafab47d-2d98-43a9-b979-75fb2d87a710"></a><a name="section-2.2"></a><p></p>
<h2>2.2  Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> </h2>
<p class="First">Cenestin therapy consists of a single tablet taken orally once daily.</p>
<dl>
<dt>•</dt>
<dd>Cenestin 0.3 mg </dd>
</dl>
<p>When prescribing solely for the treatment of symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, topical vaginal products should be considered.  </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_83459346-aaa0-4e79-8281-9cbf82c9f0eb"></a><a name="section-3"></a><p></p>
<h1>DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">Cenestin (synthetic conjugated estrogens, A) Tablets are available as:</p>
<p>0.3 mg round, green, film-coated tablets debossed with the letters, <span class="Bold">dp</span>, on one side and the number 41 on the other side.</p>
<p>0.45 mg round, orange, film-coated tablets debossed with the letters, <span class="Bold">dp</span>, on one side and the number 46 on the other side.</p>
<p>0.625 mg round, red, film-coated tablets debossed with the letters, <span class="Bold">dp</span>, on one side and the number 42 on the other side.</p>
<p>0.9 mg round, white, film-coated tablets debossed with the letters, <span class="Bold">dp</span>, on one side and the number 43 on the other side.</p>
<p>1.25 mg round, blue, film-coated tablets debossed with the letters, <span class="Bold">dp</span>, on one side and the number 44 on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_7c567cb2-c309-45e5-befe-1c158319122d"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS </h1>
<p class="First">Cenestin is contraindicated in women with any of the following conditions:   </p>
<dl>
<dt>•</dt>
<dd>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></dd>
<dt>•</dt>
<dd>Known, suspected, or history of breast cancer</dd>
<dt>•</dt>
<dd>Known or suspected estrogen-dependent neoplasia</dd>
<dt>•</dt>
<dd>Active DVT, PE, or a history of these conditions</dd>
<dt>•</dt>
<dd>Active or recent arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI), or a history of these conditions</dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with Cenestin</dd>
<dt>•</dt>
<dd>Known liver impairment or disease</dd>
<dt>•</dt>
<dd>Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders</dd>
<dt>•</dt>
<dd>Known or suspected pregnancy.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_360a5504-0f06-4db0-b83c-ff3cee1a9012"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_edd22daf-6f2f-488c-942d-8583dcde9df5"></a><a name="section-5.1"></a><p></p>
<h2>5.1  <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> </h2>
<p class="First">An increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT has been reported with estrogen-alone therapy. An increased risk of PE, DVT, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI has been reported with estrogen plus progestin therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (VTE) (for example, personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </span></p>
<p>In the WHI estrogen-alone substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted <span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>. Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, estrogen-alone therapy should be discontinued immediately.</p>
<p>Subgroup analyses of women 50 to 59 years of age suggest no increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).<span class="Sup">1</span></p>
<p>In the WHI estrogen plus progestin substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10, 000 women-years) <span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>. The increase in risk was demonstrated after the first year and persisted.<span class="Sup">1</span> Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, estrogen plus progestin therapy should be discontinued immediately. </p>
<p><span class="Italics">Coronary Heart Disease</span></p>
<p>In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as non-fatal MI, silent MI, or CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> ) was reported in women receiving estrogen-alone compared to placebo<span class="Sup">2</span><span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>.  </p>
<p>Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (8 versus 16 per 10,000 women-years).     </p>
<p>In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of CHD events reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years).<span class="Sup">1</span> An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 <span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>. </p>
<p>In postmenopausal women with documented heart disease (n = 2,763, average age 66.7 years of age), in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit.  During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease.  There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years.  Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II.   Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall.  Rates of CHD events were comparable among women in the CE (0.625 mg) plus MPA (2.5 mg) group and the placebo group in HERS, HERS II, and overall.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span></span></p>
<p>In the WHI estrogen-alone substudy, the risk of VTE (DVT and PE) was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women years). The increase in VTE risk was demonstrated during the first 2 years<span class="Sup">3</span><span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>. Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately. </p>
<p>In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE was reported in women receiving CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted<span class="Sup">4</span><span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>. Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.</p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_63bf937d-18ca-4a4c-8d3f-faab10384ae9"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Malignant Neoplasms </h2>
<p class="First"><span class="Italics">Endometrial cancer </span></p>
<p>An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</p>
<p>Clinical surveillance of all women taking estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to postmenopausal estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer.</p>
<p><span class="Italics">Breast cancer</span></p>
<p>The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the WHI substudy of daily CE (0.625 mg)-alone. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer (relative risk [RR] 0.80)<span class="Sup">5</span><span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14. 3</a>)]</span>. </p>
<p>The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA.  In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo<span class="Sup">6</span><span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups <span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>.</p>
<p>Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.</p>
<p>The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. </p>
<p>All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</p>
<p><span class="Italics">Ovarian Cancer</span></p>
<p>The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI, 0.77 - 3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.<span class="Italics"><span class="Sup">7</span></span> In some epidemiologic studies, the use of estrogen plus progestin and estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer. However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies, and some report no association.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3d6e02cd-f57d-4139-a972-8b7109ccbfc2"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> </h2>
<p class="First">In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. </p>
<p>After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years<span class="Sup">8</span><span class="Italics">[see Use in Specific Populations (<a href="#_8.5.__Geriatric">8.5</a>), and Clinical Studies (<a href="#_14.4__Women%E2%80%99s">14.4</a>)]</span>. </p>
<p>In the WHIMS estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. </p>
<p>After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.  The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48).  The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years<span class="Sup">8</span><span class="Italics">[see Use in Specific Populations (<a href="#_8.5.__Geriatric">8.5</a>), and Clinical Studies (<a href="#_14.4__Women%E2%80%99s">14.4</a>)]</span>.</p>
<p>When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent CI, 1.19-2.60). Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<span class="Sup">8</span><span class="Italics">[see Use in Specific Populations (<a href="#_8.5.__Geriatric">8.5</a></span>)<span class="Italics">, and Clinical Studies (<a href="#_14.4__Women%E2%80%99s">14.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_80603d5e-2a91-45c9-8594-f4d5d73a8a90"></a><a name="section-5.4"></a><p></p>
<h2>5.4  <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span> </h2>
<p class="First">A 2 to 4-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a8e17981-969a-4dc9-9863-758a189ed152"></a><a name="section-5.5"></a><p></p>
<h2>5.5  <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> </h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in women with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c95b7999-e005-4a3d-9cbf-ff1593f00b6e"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Visual Abnormalities </h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in women receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or renal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_317c928a-cba6-4dec-8700-b8ea3831bbb0"></a><a name="section-5.7"></a><p></p>
<h2>5.7  Addition of a Progestin when a Woman has not had a Hysterectomy </h2>
<p class="First">Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would be induced by estrogen treatment alone. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer. </p>
<p>There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include a possible increased risk of breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_39de5228-7f9d-41c2-b00f-c6bb0f73f231"></a><a name="section-5.8"></a><p></p>
<h2>5.8  Elevated Blood Pressure </h2>
<p class="First">In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5b52e46f-aa9a-4dd0-9e25-aa1fe2921ded"></a><a name="section-5.9"></a><p></p>
<h2>5.9  <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> </h2>
<p class="First">In women with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.  Consider discontinuation of treatment if <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_135d1c78-93b5-44dc-9fd9-69517dbf8625"></a><a name="section-5.10"></a><p></p>
<h2>5.10  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span> </h2>
<p class="First">Estrogens may be poorly metabolized in women with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For women with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_33982655-b319-499c-a18c-86abaf7404d7"></a><a name="section-5.11"></a><p></p>
<h2>5.11  <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> </h2>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_10e882ed-90e9-4757-8d2a-f9b3974a1994"></a><a name="section-5.12"></a><p></p>
<h2>5.12  <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> </h2>
<p class="First">Estrogens may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Women with conditions that might be influenced by this factor, such as a cardiac or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, warrant careful observation when estrogen-alone is prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1f131322-7f4d-4760-8893-158deae3c47b"></a><a name="section-5.13"></a><p></p>
<h2>5.13  <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> </h2>
<p class="First">Estrogen therapy should be used with caution in women with <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span> as estrogen-induced <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c4da300f-aa7a-4781-8dec-8f7006e54bf6"></a><a name="section-5.14"></a><p></p>
<h2>5.14  Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> </h2>
<p class="First">A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For women known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a29d7d6d-ea3e-4689-9c77-547d3be20a6b"></a><a name="section-5.15"></a><p></p>
<h2>5.15  <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span> </h2>
<p class="First">Exogenous estrogens may exacerbate symptoms of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in women with <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">hereditary angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_39ec347e-ec7e-4b82-810d-f8599a12abad"></a><a name="section-5.16"></a><p></p>
<h2>5.16  Exacerbation of Other Conditions </h2>
<p class="First">Estrogen therapy may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a6eba591-19f6-4483-bf13-d7e1b7fff698"></a><a name="section-5.17"></a><p></p>
<h2>5.17  Laboratory Tests </h2>
<p class="First">Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cb2e2861-f142-4a54-8e22-262232880ca3"></a><a name="section-5.18"></a><p></p>
<h2>5.18  Drug/Laboratory Test Interactions </h2>
<p class="First">Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity.</p>
<p>Increased TBG levels leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone.</p>
<p>Other binding proteins may be elevated in serum for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>).</p>
<p>Increased plasma high-density lipoprotein (HDL) and HDL2 <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> subfraction concentrations, reduced low-density lipoprotein (LDL) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased triglyceride levels.</p>
<p>Impaired glucose tolerance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_1c32dd0d-eb1b-44f0-8e21-7b5c9b347bf8"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS </h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> <span class="Italics">[see Boxed Warning, Warning and Precautions (<a href="#_5.1__Cardiovascular">5.1</a>)]</span>
</dd>
<dt>•</dt>
<dd>Malignant Neoplasms <span class="Italics">[see Boxed Warning, Warning and Precautions (<a href="#_5.2.__Malignant">5.2</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a5add67d-dd73-4b2c-8e00-ee93ae603ef5"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>In a 12-week clinical trial that included 72 women treated with 0.625 mg and 2 x 0.625 mg Cenestin and 48 women treated with placebo, adverse reactions that occurred at a rate of ≥ 5 percent are summarized in Table <a href="#TABLE_1">1</a>.</p>
<dl>
<dt> </dt>
<dd>Table 1: 	Number (%) of Patients with Adverse Reactions with ≥ 5 Percent </dd>
<dt> </dt>
<dd>Occurrence Rate By Body System and Treatment Group</dd>
</dl>
<table width="100%">
<col width="44%">
<col width="16%">
<col width="16%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Body System<br> Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cenestin<span class="Sup">a</span><br>0.625 mg and <br>2 x 0.625 mg <br>n=72</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><br>Placebo <br>n=48</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><br>Total <br>n=120</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Any Adverse Reaction (%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">68 (94)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">43 (90)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">111 (93)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Body As A Whole</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">20 (28)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">11 (23)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">31 (26)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">24 (33)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">20 (42)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">44 (37)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">49 (68)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">32 (67)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">81 (68)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">8 (11)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">9 (19)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">17 (14)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Digestive System</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (10)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (6)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">21 (29)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">14 (29)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">35 (29)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">13 (18)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">9 (19)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">22 (18)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (7)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">6 (5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Metabolic and Nutritional </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (10)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">6 (13)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">13 (11)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Nervous System</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">20 (28)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">18 (38)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">38 (32)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">8 (11)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (10)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">13 (11)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">30 (42)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">23 (48)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">53 (44)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg Cramps</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (10)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (6)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">24 (33)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">15 (31)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">39 (33)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">12 (17)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">12 (25)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">24 (20)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Urogenital System</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">21 (29)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (15)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">28 (23)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast Pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">4 (6)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (6)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 (14)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (6)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">13 (11)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">Metrorrhagia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 (14)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (6)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">13 (11)</p></td>
</tr>
</tbody>
</table>
<p>In a second 12-week clinical trial that included 52 women treated with 0.45 mg Cenestin and 51 women treated with placebo, adverse reactions that occurred at a rate of &gt;5 percent are summarized in Table <a href="#TABLE_2">2</a>.</p>
<dl>
<dt> </dt>
<dd><span class="Bold">Table 2: 	Number (%) of Patients with a ≥ 5 Percent Occurrence Rate by Body System</span></dd>
<dt> </dt>
<dd><span class="Bold">and Treatment Group</span></dd>
</dl>
<table width="100%">
<col width="44%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Body System and Term</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cenestin <br>0.45 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Any Adverse Reaction (%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">40 (75.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">39 (76.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Body As A Whole</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">20 (37.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">24 (47.1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">6 (11.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (13.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">6 (11.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">8 (15.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (1.9%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">6 (11.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">6 (11.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (2.0%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Pain abdominal</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (9.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Cardiovascular</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (9.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 (19.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Vasodilations</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (3.8%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">4 (7.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Digestive</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">8 (15.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (13.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (9.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (3.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Metabolic and Nutritional</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (9.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increase</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (3.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Musculoskeletal</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (9.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">6 (11.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (9.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (9.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (3.8%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">6 (11.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Neurological</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">15 (28.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">19 (37.3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (2.0%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (9.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (3.8%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (13.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">4 (7.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Respiratory</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 (18.9%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">6 (11.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (5.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (3.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Urogenital</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">19 (35.8%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (13.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Endometrial thickening</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 (18.9%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">4 (7.8%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">4 (7.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (2.0%)</p></td>
</tr>
</tbody>
</table>
<p>If a subject experiences the same event more than once, the first occurrence<span class="Sup"></span>is tabulated.</p>
<p>In a 16-week clinical trial that included 36 women treated with 0.3 mg Cenestin and 34 women treated with placebo, adverse reactions that occurred at a rate of &gt;5 percent are summarized in Table <a href="#TABLE_3">3</a>.</p>
<dl>
<dt> </dt>
<dd><span class="Bold">Table 3:	Number (%) of Patients with Adverse Reactions with ≥ 5 Percent </span></dd>
<dt> </dt>
<dd><span class="Bold">Occurrence Rate By Body System and Treatment Group</span></dd>
</dl>
<table width="100%">
<col width="44%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Body System and Term</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cenestin <br>0.30 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Body as a Whole </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">22 (60) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">13 (38) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (8) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (3) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (8) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (3) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Injury <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">Accident</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (5) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (3) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (5) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (3) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">Cyst</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (5) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0 (0) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (8) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (6) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Digestive </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 (27) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">8 (24) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">4 (11) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (6) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (5) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (3) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (8) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0 (0) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased Appetite</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (5) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0 (0) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Neurological </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (19) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7 (21) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (8) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0 (0) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Urogenital </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">22 (60) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">16 (47) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">Leukorrhea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">12 (32) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (15) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">9 (24) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 (15) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary Incontinence</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 (8) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 (3) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">Metrorrhagia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (5) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0 (0) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 (5) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0 (0) </p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3c393b56-5045-49e7-ac49-f59d367b20ec"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Post Marketing Experience </h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Cenestin.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p>
<p>Investigations: <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span></p>
<p>Metabolism &amp; Nutrition Disorders: <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span></p>
<p>Neoplasms: breast cancer</p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p>
<p>Psychiatric Disorder: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></p>
<p>Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>: <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="4114004" conceptname="Swelling of breast">breast swelling</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span></p>
<p>Skin &amp; Subcutaneous Tissue Disorders: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">pruritus generalized</span>, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_c55afbfa-3354-4d4f-9592-fecfa82b0c65"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS </h1>
<p class="First">No drug-drug interaction studies have been conducted with Cenestin</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4ded6e32-4002-4f56-a76d-366eee1f4e02"></a><a name="section-7.1"></a><p></p>
<h2>7.1  Metabolic Interactions </h2>
<p class="First"><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers and inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John’s wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_aaa293ad-afb8-487a-9f07-91f1e1b17979"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_a9e7c2f1-40dc-4d3d-8ca3-1ba771c2ba19"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy </h2>
<p class="First">Cenestin should not be used during pregnancy <span class="Italics">[See Contraindications (<a href="#ID_360a5504-0f06-4db0-b83c-ff3cee1a9012">4</a>)]</span>. There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_017c3082-5501-4daf-902c-4f1ac43f6634"></a><a name="section-8.2"></a><p></p>
<h2>8.3  Nursing Mothers </h2>
<p class="First">Cenestin should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogens have been identified in the breast milk of women receiving estrogen-alone therapy. Caution should be exercised when Cenestin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_c2111db8-e04e-4587-8c95-28dc2287599f"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use </h2>
<p class="First">Cenestin is not indicated in children. Clinical studies have not been conducted in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_42ffdf7b-ef9b-4152-bdbc-2244c47ea8f1"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use </h2>
<p class="First">There have not been sufficient numbers of geriatric women involved in studies utilizing Cenestin to determine whether those over 65 years of age differ from younger subjects in their response to Cenestin. </p>
<p><span class="Italics">The Women’s Health Initiative Studies</span></p>
<p>In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women greater than 65 years of age <span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>.</p>
<p>In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer in women greater than 65 years of age <span class="Italics">[see Clinical Studies (<a href="#_14.3__Women%E2%80%99s">14.3</a>)]</span>.</p>
<p><span class="Italics">The Women’s Health Initiative Memory Study</span></p>
<p>In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women receiving estrogen-alone or estrogen plus progestin when compared to placebo. <span class="Italics">[see Warnings and Precautions (<a href="#_5.3__Probable">5.3</a>), and Clinical Studies (<a href="#_14.4__Women%E2%80%99s">14.4</a>)]</span>. </p>
<p>Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<span class="Sup">8</span><span class="Italics">[see Warnings and Precautions (<a href="#_5.3__Probable">5.3</a>), and Clinical Studies (<a href="#_14.4__Women%E2%80%99s">14.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e792a80c-15d2-4724-a331-d5da754fc998"></a><a name="section-8.5"></a><p></p>
<h2>8.6  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of Cenestin has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7d6dd992-d97e-4635-8820-f238fb5a9abf"></a><a name="section-8.6"></a><p></p>
<h2>8.7  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of Cenestin has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_11e1fdb2-9f91-46eb-a930-af9a4e2f88c5"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE </h1>
<p class="First">Overdosage of estrogen may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in women.  Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> consists of discontinuation of Cenestin therapy with institution of appropriate symptomatic care.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_920f5107-bbc1-4f23-a42e-bfda9412f9c8"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION </h1>
<p class="First">Cenestin (synthetic conjugated estrogens, A) tablets contain a blend of nine (9) synthetic estrogenic substances. The estrogenic substances are sodium estrone sulfate, sodium equilin sulfate, sodium 17α-dihydroequilin sulfate, sodium 17α-estradiol sulfate, sodium 17β-dihydroequilin sulfate, sodium 17α-dihydroequilenin sulfate, sodium 17β-dihydroequilenin sulfate, sodium equilenin sulfate and sodium 17β-estradiol sulfate.</p>
<p>The structural formulae for these estrogens are:</p>
<div class="Figure">
<a name="id469631568"></a><img alt="Sodium Estrone Sulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-01.jpg">
</div>
<p><span class="Bold">Sodium Estrone Sulfate</span></p>
<div class="Figure">
<a name="id469631569"></a><img alt="Sodium Equilin Sulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-02.jpg">
</div>
<p><span class="Bold">Sodium Equilin Sulfate</span></p>
<div class="Figure">
<a name="id469631570"></a><img alt="Sodium 17α-Dihydroequilin Sulfate " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-03.jpg">
</div>
<p><span class="Bold">Sodium 17α-Dihydroequilin Sulfate </span></p>
<div class="Figure">
<a name="id469631571"></a><img alt="Sodium 17α-Estradiol Sulfate " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-04.jpg">
</div>
<p><span class="Bold">Sodium 17α-Estradiol Sulfate </span></p>
<div class="Figure">
<a name="id469631572"></a><img alt="Sodium 17β-Dihydroequilin Sulfate " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-05.jpg">
</div>
<p><span class="Bold">Sodium 17β-Dihydroequilin Sulfate </span></p>
<div class="Figure">
<a name="id469631573"></a><img alt="Sodium 17α-Dihydroequilenin Sulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-06.jpg">
</div>
<p><span class="Bold">Sodium 17α-Dihydroequilenin Sulfate</span></p>
<div class="Figure">
<a name="id469631574"></a><img alt="Sodium 17β-Dihydroequilenin Sulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-07.jpg">
</div>
<p><span class="Bold">Sodium 17β-Dihydroequilenin Sulfate</span></p>
<div class="Figure">
<a name="id469631575"></a><img alt="Sodium Equilenin Sulfate " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-08.jpg">
</div>
<p><span class="Bold">Sodium Equilenin Sulfate </span></p>
<div class="Figure">
<a name="id469631576"></a><img alt="Sodium 17β-Estradiol Sulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-09.jpg">
</div>
<p><span class="Bold">Sodium 17β-Estradiol Sulfate</span></p>
<p>Tablets for oral administration, are available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg strengths of synthetic conjugated estrogens, A. Tablets also contain the following inactive ingredients: ethylcellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80 (except 0.45 mg tablets ), pregelatinized starch, titanium dioxide, and triethyl citrate.</p>
<dl>
<dt> </dt>
<dd><dl>
<dt>•</dt>
<dd>0.3 mg tablets also contain FD&amp;C Blue No. 2 aluminum lake and D&amp;C Yellow No. 10 aluminum lake.</dd>
<dt>•</dt>
<dd>0.45 mg tablets also contain FD&amp;C Yellow No. 6/Sunset Yellow FCF lake.</dd>
<dt>•</dt>
<dd>0.625 mg tablets also contain FD&amp;C Red No. 40 aluminum lake.</dd>
<dt>•</dt>
<dd>0.9 mg tablets do not contain additional color additives.</dd>
<dt>•</dt>
<dd>1.25 mg tablets also contain FD&amp;C Blue No. 2 aluminum lake.</dd>
</dl></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_4cbb652a-5d52-4ff9-957a-58a11bbd41c3"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_1f2bc632-c436-4cd1-870e-5553ba8e42fd"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action </h2>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level.</p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.</p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. </p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_3c7148e0-6efa-412d-96b5-fc5b67d067c4"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics </h2>
<p class="First">There are no pharmacodynamic data for Cenestin</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_8086087d-62a0-48b5-9c51-7149750f6612"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics </h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>Synthetic conjugated estrogens, A are soluble in water and are absorbed from the gastrointestinal tract after release from the drug formulation. The effect of food on the bioavailability of synthetic conjugated estrogens, A from Cenestin has not been studied.</p>
<dl>
<dt> </dt>
<dd><span class="Bold">Table 4:	PHARMACOKINETIC PARAMETERS FOR UNCONJUGATED AND </span></dd>
<dt> </dt>
<dd><span class="Bold">CONJUGATED ESTROGENS IN HEALTHY POSTMENOPAUSAL </span></dd>
<dt> </dt>
<dd><span class="Bold">WOMEN UNDER FASTING CONDITIONS</span></dd>
</dl>
<table width="100%">
<col width="18%">
<col width="7%">
<col width="11%">
<col width="8%">
<col width="10%">
<col width="15%">
<col width="3%">
<col width="23%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="8" valign="top">
<p class="First"><span class="Bold">Pharmacokinetic Parameters of Unconjugated Estrogens Following a</span></p>
<p><span class="Bold">Dose of 2 x 0.625 mg Cenestin</span></p>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" colspan="2" valign="top"><p class="First">Drug</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">Cmax (pg/mL) (CV%)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
<p class="First">Tmax (h) </p>
<p>(CV%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">AUC0-72h (pg•hr/mL) (CV%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" colspan="2" valign="top"><p class="First">Baseline-corrected estrone</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">84.5 (41.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">8.25 (35.6)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">1749 (43.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" colspan="2" valign="top"><p class="First">Equilin</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">45.6 (47.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">7.78 (28.8)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">723 (67.9)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="8" valign="top">
<p class="First"><span class="Bold">Pharmacokinetic Parameters of Conjugated Estrogens Following a</span></p>
<p><span class="Bold">Dose of 2 x 0.625 mg Cenestin</span></p>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Drug</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">Cmax (pg/mL) (CV%)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
<p class="First">Tmax (h) </p>
<p>(CV%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
<p class="First">t ½ (h) </p>
<p>(CV%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">AUC0-72h (pg•hr/mL) </p>
<p>(CV%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline-corrected estrone</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">4.43 (40.4)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">7.7 (30.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">10.6 (25.4)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">69.89 (39.2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Equilin</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">3.27 (43.5)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">5.8 (31.1)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">9.7 (23.0)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">46.46 (47.5)</p></td>
</tr>
</tbody>
</table>
<div class="Figure">
<a name="id469633080"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-10.jpg">
</div>
<p><span class="Italics">Distribution</span></p>
<p>The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) and albumin.</p>
<p><span class="Italics">Metabolism</span></p>
<p>Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant portion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.</p>
<p><span class="Italics">Excretion</span></p>
<p>Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.</p>
<p><span class="Italics">Use in Specific Populations</span></p>
<p>No pharmacokinetic studies were conducted in specific populations, including patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_f2739cf3-2d43-4773-87fe-c633381f7fb6"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY </h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_5d2a5aa1-0bba-4984-8a24-43a96055ba9a"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<p class="First">Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_11f8aa28-76a4-4bfb-9827-c45a2ef56917"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_786f8383-7d30-4e12-a627-17738f473da2"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Effects on Vasomotor Symptoms </h2>
<p class="First">A randomized, placebo-controlled multicenter clinical study was conducted evaluating the effectiveness of Cenestin for the treatment of moderate to severe vasomotor symptoms in 120 postmenopausal women between 38 and 66 years of age (68% were Caucasian). Patients were randomized to receive either placebo or 0.625 mg Cenestin daily for 12 weeks. Dose titration was allowed after one week of treatment. The starting dose was either doubled (2 x 0.625 mg Cenestin or placebo taken daily) or reduced (0.3 mg Cenestin or placebo taken daily), if necessary. Efficacy was assessed at 4 and 12 weeks of treatment. By week 12, 10% of the study participants remained on a single 0.625 mg Cenestin tablet daily while 77% required two (0.625 mg) tablets daily. The results in Table <a href="#TABLE_5">5</a> indicate that compared to placebo, Cenestin produced a reduction in moderate to severe vasomotor symptoms at weeks 4 and 12. </p>
<p>A second randomized, placebo-controlled multicenter clinical study was conducted evaluating the effectiveness of 0.45 mg Cenestin tablets, for the treatment of moderate to severe vasomotor symptoms in 104 menopausal women between 52 and 74 years of age (76% were Caucasian). Patients were randomized to receive either placebo or 0.45 mg Cenestin daily for 12 weeks. Efficacy was assessed at 4 and 12 weeks of treatment. The mean change in the number of moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> per week shown in Table <a href="#TABLE_5">5</a> indicate that compared to placebo, 0.45 mg Cenestin produced a reduction in moderate to severe vasomotor symptoms at weeks 4 and 12. A corresponding reduction in the severity of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> was demonstrated at weeks 5 and 12.</p>
<dl>
<dt> </dt>
<dd>Table 5:	Clinical Response<span class="Sup">a</span>	 Mean Change in the Number of Moderate to Severe Hot</dd>
<dt> </dt>
<dd>Flushes per Week, 0.625 mg and 2 x 0.625 mg Cenestin, ITT Population</dd>
</dl>
<table width="100%">
<col width="31%">
<col width="31%">
<col width="31%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cenestin<span class="Sup">b</span> 0.625 mg and 2 x 0.625 mg (n=70)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Placebo (n=47)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Mean # (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">96.8 (42.6)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">94.1 (33.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Week 4</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Mean # (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">28.7 (28.8)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">45.7 (36.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Mean Change from <br> Baseline (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">-68.1 (43.9)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">-48.4 (46.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> P-value vs. Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">p=.022</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Week 12</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Mean # (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">16.5 (25.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">37.8 (38.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Mean Change from <br> Baseline (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">-80.3 (50.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">-56.3 (48.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> P-value vs. Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">p=0.10</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First">Mean = Arithmetic Mean, SD = Standard Deviation</p></td></tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>Table 6: 	Clinical Response<span class="Sup">a</span>	 Mean Change in the Number of Moderate to Severe Hot </dd>
<dt> </dt>
<dd>Flushes per Week, 0.45 mg Cenestin, ITT Population</dd>
</dl>
<table width="100%">
<col width="31%">
<col width="31%">
<col width="31%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cenestin 0.45 mg (n=53)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Placebo (n=51)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Mean # (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">95.9 (37.0)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">95.9 (41.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Week 4</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Mean # (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">45.7 (45.9)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">59.4 (46.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Mean Change from <br> Baseline (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">-50.3 (35.4)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">-36.5 (42.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> P-value vs. Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">p=0.14</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Week 12</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Mean # (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">26.1 (43.0)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">50.5 (48.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Mean Change from <br> Baseline (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">-69.9 (38.1)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">-45.4 (44.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> P-value vs. Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">p&lt;.001</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First">Mean = Arithmetic Mean, SD = Standard Deviation</p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_217efcf3-5fd0-43c5-b445-1409407d9922"></a><a name="section-13.2"></a><p></p>
<h2>14.2  Effects on Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> </h2>
<p class="First">The effects of 0.3 mg Cenestin on moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> were confirmed in a 16-week, randomized, placebo-controlled, multicenter clinical study in 72 postmenopausal women between 30 and 77 years of age (53 percent were Caucasian). Patients were randomized to receive either placebo or 0.3 mg Cenestin daily for 16 weeks. Efficacy was assessed at weeks 12 and 16 for vaginal wall <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">cytology</span> and week 16 for vaginal pH. Results for percent of superficial cells from a maturation index of the vaginal mucosa are shown in Figure 2. Mean vaginal pH decreased from a baseline of 6.20 to 5.14 for Cenestin and increased to 6.15 from a baseline of 6.03 for placebo. </p>
<p><a name="id469636064"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-11.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_611863b8-a482-4450-9a8c-55f781b396c6"></a><a name="section-13.3"></a><p></p>
<h2>14.3  Women’s Health Initiative Studies </h2>
<p class="First">The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of either the use of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases.  The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as the primary adverse outcome.  A “global index? included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes.  These substudies did not evaluate the effects of CE-alone or CE plus MPA on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</p>
<p><span class="Italics">WHI Estrogen-Alone Substudy</span></p>
<p>The WHI estrogen-alone substudy was stopped early because an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen alone in predetermined primary endpoints.  Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow-up of 7.1 years are presented in Table <a href="#TABLE_6">6</a>.</p>
<dl>
<dt> </dt>
<dd>Table 7:	Relative and Absolute Risk Seen In the Estrogen-Alone Substudy of WHI<span class="Sup">a</span>
</dd>
</dl>
<table width="100%">
<col width="23%">
<col width="23%">
<col width="23%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<p class="First"><span class="Bold">Relative Risk</span></p>
<p><span class="Bold">CE vs. Placebo</span></p>
<p><span class="Bold">(95% nCI<span class="Sup">b</span>)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">CE</span></p>
<p><span class="Bold">n=5,310</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">n=5,429</span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Absolute Risk per 10,000 </span></p>
<p><span class="Bold">Women-Years</span></p>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">CHD events<span class="Sup">c</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.95 (0.78- 1.16)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">54</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">57</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Italics">     Nonfatal MI<span class="Sup">c</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">0.91 (0.73-1.14)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">40</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">43</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Italics">     CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><span class="Sup">c </span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">1.01(0.71- 1.43)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">16</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">16</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span><span class="Sup">c</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.33 (1.05-1.68)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">45</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">33</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Italics">     <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span><span class="Sup">c</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.55 (1.19-2.01)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">38</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><span class="Sup">c,d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.47 (1.06-2.06)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Pulmonary <br><span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span><span class="Sup">c</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.37 (0.90-2.07)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Invasive breast cancer<span class="Sup">c</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.80 (0.62-1.04)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">28</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">34</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Colorectal cancer<span class="Sup">e</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.08 (0.75-1.55)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><span class="Sup">c</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.65 (0.45-0.94)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">19</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><span class="Sup">c,d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.64 (0.44-0.93)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">18</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">c,d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.58 (0.47-0.72)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">35</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">59</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">c,d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.71 (0.64-0.80)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">144</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">197</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to other causes<span class="Sup">e,f </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.08 (0.88-1.32)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">53</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Overall mortality<span class="Sup">c,d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.04 (0.88-1.22)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">79</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">75</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Global index<span class="Sup">g</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.02 (0.91-1.13)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">206</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">201</p></td>
</tr>
</tbody>
</table>
<p>For those outcomes included in the WHI “global index? that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while the absolute risk reduction per 10,000 women-years was 7 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>.<span class="Sup">9</span> The absolute excess risk of events included in the “global index? was a non-significant 5 events per 10,000 women-years.  There was no difference between the groups in terms of all-cause mortality.</p>
<p>No overall difference for primary CHD events (nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow up of 7.1 years. See Table <a href="#TABLE_7">7</a>.</p>
<p>Centrally adjudicated results for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> subtype or severity, including fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>, and this excess risk was present in all subgroups of women examined.<span class="Sup">10</span> See Table <a href="#TABLE_7">7</a>.</p>
<p>Timing of the initiation of estrogen-alone therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen-alone substudy stratified by age showed in women 50 to 59 years of age, a non-significant trend toward reduced risk for CHD [hazard ratio (HR) 0.63 (95 percent CI, 0.36-1.09)] and overall mortality [HR 0.71 (95 percent CI, 0.46-1.11)].   </p>
<p><span class="Italics">WHI Estrogen Plus Progestin Substudy</span></p>
<p>The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the “global index?.  The absolute excess risk of events included in the “global index? was 19 per 10,000 women-years.    </p>
<p>For those outcomes included in the WHI “global index? that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women- years in the group treated with CE plus MPA were 7 more CHD events, 8 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. </p>
<p>Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table <a href="#TABLE_8">8</a>. These results reflect centrally adjudicated data after an average follow-up of 5.6 years.</p>
<dl>
<dt> </dt>
<dd>Table 8:	Relative And Absolute Risk Seen in the Estrogen Plus Progestin Substudy of </dd>
<dt> </dt>
<dd>WHI at an Average of 5.6 Years <span class="Sup">a,b</span>
</dd>
</dl>
<table width="100%">
<col width="23%">
<col width="23%">
<col width="23%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><p class="First"><span class="Bold">Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Relative Risk <br>CE/MPA vs. Placebo<br>(95% nCI<span class="Sup">c</span>)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">CE/MPA</span></p>
<p><span class="Bold">n = 8,506</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">n = 8,102 </span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
<p class="First"><span class="Bold">Absolute Risk per 10,000</span></p>
<p><span class="Bold">Women-Years</span></p>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">CHD events</p>
<p><span class="Italics">Non-fatal MI</span></p>
<p><span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">1.23 (0.99-1.53)</p>
<p><span class="Italics">1.28 (1.00-1.63)</span></p>
<p><span class="Italics">1.10 (0.70-1.75)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">41</p>
<p><span class="Italics">31</span></p>
<p><span class="Italics">8</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">34</p>
<p><span class="Italics">25</span></p>
<p><span class="Italics">8</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.31 (1.03-1.68)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">33</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">1.44 (1.09 -1.90)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">26</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">18</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><span class="Sup">d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.95 (1.43 – 2.67)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Pulmonary <br><span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.13 (1.45-3.11)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Invasive breast cancer<span class="Sup">e</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.24 (1.01-1.54)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">41</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">33</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Colorectal cancer</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.61 (0.42-0.87)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Endometrial cancer<span class="Sup">d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.81 (0.48-1.36)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Cervical cancer<span class="Sup">d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.44 (0.47-4.42)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.67 (0.47-0.96)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><span class="Sup">d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.65 (0.46-0.92)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">17</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.71 (0.59-0.85)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">44</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">62</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.76 (0.69-0.83)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">152</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">199</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Overall Mortality<span class="Sup">f</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.00 (0.83-1.19)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">52</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">52</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Global Index<span class="Sup">g</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.13(1.02-1.25)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">184</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">165</p></td>
</tr>
</tbody>
</table>
<p>Timing of the initiation of estrogen therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy stratified by age showed in women 50 to 59 years of age a non-significant trend toward reduced risk for overall mortality [HR 0.69 (95 percent CI, 0.44 – 1.07)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cb26f28a-dc95-4348-b4e6-697a6ecc2e9a"></a><a name="section-13.4"></a><p></p>
<h2>14.4  Women’s Health Initiative Memory Study </h2>
<p class="First">The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age; 36 percent were 70 to 74 years of age; and 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo.</p>
<p>After an average follow-up of 5.2 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included Alzheimer’s disease (AD), <span class="product-label-link" type="condition" conceptid="379778" conceptname="Multi-infarct dementia">vascular dementia</span> (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#_5.3__Probable">5.3</a>), and Use in Specific Populations (<a href="#_8.5.__Geriatric">8.5</a>)]</span>.</p>
<p>The WHIMS estrogen plus progestin ancillary study enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 year of age, 35 percent were 70 to 74 years of age, and 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo. </p>
<p>After an average follow-up of 4 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48) compared to placebo. The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 45 versus 22 per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included AD, VaD and mixed type (having features of both AD and CaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#_5.3__Probable">5.3</a>), and Use in Specific Populations (<a href="#_8.5.__Geriatric">8.5</a>)]</span>. </p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent CI, 1.19-2.60).  Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#_5.3__Probable">5.3</a>), and Use in Specific Populations (<a href="#_8.5.__Geriatric">8.5</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_a8afc890-b0ca-4e12-a70b-97197126c124"></a><a name="section-14"></a><p></p>
<h1>15  REFERENCES </h1>
<dl>
<dt>1.</dt>
<dd>Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span>. JAMA. 2007;297:1465-1477. </dd>
<dt>2.</dt>
<dd>Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med. 2006;166:357-365. </dd>
<dt>3.</dt>
<dd>Curb JD, et al. <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span> and Conjugated Equine Estrogen in Women Without a Uterus. Arch Int Med. 2006;166:772-780. </dd>
<dt>4.</dt>
<dd>Cushman M, et al. Estrogen Plus Progestin and Risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span>. JAMA. 2004;292:1573-1580. </dd>
<dt>5.</dt>
<dd>Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA. 2006;295:1647-1657. </dd>
<dt>6.</dt>
<dd>Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. JAMA. 2003;289:3234-3253. </dd>
<dt>7.</dt>
<dd>Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. JAMA. 2003;290:1739-1748. </dd>
<dt>8.</dt>
<dd>Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> and Mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">Cognitive Impairment</span> in Postmenopausal Women. JAMA. 2004;291:2947-2958. </dd>
<dt>9.</dt>
<dd>Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. J Bone Miner Res. 2006;21:817-828. </dd>
<dt>10.</dt>
<dd>Hendrix SL, et al. Effects of Conjugated Equine Estrogen on <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in the Women's Health Initiative. Circulation. 2006;113:2425-2434.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_02ba551e-4505-4517-97ce-4dbf265d66da"></a><a name="section-15"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a5760a8c-ca48-4ac8-95a0-3f1a70b8a45a"></a><a name="section-15.1"></a><p></p>
<h2>16.1  How Supplied </h2>
<p class="First">Cenestin (synthetic conjugated estrogens, A) Tablets are available as:</p>
<table width="100%">
<col width="13%">
<col width="75%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0.3 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Round, green, film-coated, and are debossed with the letters, <span class="Bold">dp</span>, on one side and the number, 41 on the other side.</p>
<p>Available in bottles of: 100          NDC 51285-441-02</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.45 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Round, orange, film-coated, and are debossed with the letters, <span class="Bold">dp</span>, on one side and the number, 46 on the other side.</p>
<p>Available in bottles of: 100          NDC 51285-446-02</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.625 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Round, red, film-coated, and are debossed with the letters, <span class="Bold">dp</span>, on one side and the number, 42 on the other side.</p>
<p>Available in bottles of: 100          NDC 51285-442-02</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.9 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Round, white, film-coated, and are debossed with the letters, <span class="Bold">dp</span>, on one side and the number, 43 on the other side.</p>
<p>Available in bottles of: 100          NDC 51285-443-02</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.25 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Round, blue, film-coated, and are debossed with the letters, <span class="Bold">dp</span>, on one side and the number, 44 on the other side.</p>
<p>Available in bottles of: 100          NDC 51285-444-02</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c2bb208d-18ee-446d-bb86-67b59f6cf223"></a><a name="section-15.2"></a><p></p>
<h2>16.2  Storage and Handling </h2>
<p class="First">Store at 20 to 25°C (68-77°F); excursions are permitted to 15 to 30°C (59 to 86°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in tight container.</p>
<p>Dispense in child-resistant packaging.</p>
<p>Keep out of the reach of children.</p>
<p>Pharmacist: Include one “Information for the patient? leaflet with each package dispensed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_29f3fa77-8796-4d78-8151-bb23a9bbf04d"></a><a name="section-16"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION </h1>
<p class="First">See FDA-approved patient labeling (Patient Information).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fa888d08-2be9-4e87-a8f1-fa29260a5881"></a><a name="section-16.1"></a><p></p>
<h2>17.1  <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span> </h2>
<p class="First">Inform postmenopausal women of the importance of reporting <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to their healthcare provider as soon as possible <span class="Italics">[see Warnings and Precautions (<a href="#_5.2.__Malignant">5.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_93ba40d5-175d-4e34-9e8a-f7928a8dc125"></a><a name="section-16.2"></a><p></p>
<h2>17.2  Possible Serious Adverse Reactions with Estrogen-Alone Therapy </h2>
<p class="First">Inform postmenopausal women of possible serious adverse reactions of estrogen-alone therapy including <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, Malignant Neoplasms, and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> <span class="Italics">[see Warnings and Precautions (<a href="#_5.1__Cardiovascular">5.1</a>, <a href="#_5.2.__Malignant">5.2</a>, <a href="#_5.3__Probable">5.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a8e9931e-000d-414c-8647-59a9dc4454d5"></a><a name="section-16.3"></a><p></p>
<h2>17.3  Possible Less Serious but More Common Adverse Reactions with Estrogen-Alone Therapy </h2>
<p class="First">Inform postmenopausal women of possible less serious but common adverse reactions of estrogen-alone therapy such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Manufactured By:</p>
<p>Teva Women’s Health, Inc.</p>
<p>Subsidiary of Teva Pharmaceuticals USA, Inc.</p>
<p>North Wales, PA 19454</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_1d845695-4e14-42b6-8dec-a0c23dfd5ba6"></a><a name="section-17"></a><p></p>
<h1>Patient Information </h1>
<p class="First"><span class="Bold">CENESTIN<span class="Sup">®</span> (sin nes tin)</span></p>
<p><span class="Bold">(synthetic conjugated estrogens, A) </span></p>
<p><span class="Bold">Tablets</span></p>
<p>Read this Patient Information before you start taking CENESTIN and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span> or your treatment.</p>
<table cellpadding="5.75pt" width="97%">
<col width="100%">
<tbody class="Headless">
<tr class="First"><td class="Lrule Toprule" valign="top">
<p class="First"><span class="Bold">What is the most important information I should know about CENESTIN (an estrogen mixture)?</span></p>
<dl>
<dt>•</dt>
<dd>Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> right away while you are taking CENESTIN. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</dd>
<dt>•</dt>
<dd>Do not use estrogen-alone to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (decline in brain function).</dd>
<dt>•</dt>
<dd>Using estrogen-alone may increase your chances of getting <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or blood clots. </dd>
<dt>•</dt>
<dd>Using estrogen-alone may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years of age or older. </dd>
<dt>•</dt>
<dd>Do not use estrogens with progestins to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</dd>
<dt>•</dt>
<dd>Using estrogens with progestins may increase your chances of getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, or blood clots.</dd>
<dt>•</dt>
<dd>Using estrogens with progestins may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years of age or older.</dd>
<dt>•</dt>
<dd>You and your healthcare provider should talk regularly about whether you still need treatment with CENESTIN. </dd>
</dl>
</td></tr>
<tr class="Last"><td class="Botrule Lrule" valign="top"></td></tr>
</tbody>
</table>
<p><span class="Bold">What is CENESTIN?</span></p>
<p>CENESTIN is a prescription medicine that contains a mixture of estrogen hormones.</p>
<p><span class="Bold">What is CENESTIN used for?</span></p>
<p>CENESTIN is used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to:</p>
<dl>
<dt>•</dt>
<dd><span class="Bold">reduce moderate or severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span></span></dd>
<dt> </dt>
<dd>Estrogens are hormones made by a woman’s ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the “change of life? or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (the end of monthly menstrual periods). Sometimes, both ovaries are removed during an operation before natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> takes place. The sudden drop in estrogen levels causes “surgical menopause?.</dd>
<dt> </dt>
<dd>When estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden intense episodes of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (“hot flashes? or “hot flushes?). In some women, the symptoms are mild, and they will not need to take estrogens. In other women, symptoms can be more severe. </dd>
<dt>•</dt>
<dd><span class="Bold">treat moderate to severe menopausal changes in and around the vagina</span></dd>
<dt> </dt>
<dd>You and your healthcare provider should talk regularly about whether you still need treatment with CENESTIN to control these problems. If you use CENESTIN only to treat your menopausal changes in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you.</dd>
</dl>
<p><span class="Bold">Who should not take CENESTIN?</span></p>
<p><span class="Bold">Do not take CENESTIN if you:</span></p>
<dl>
<dt>·</dt>
<dd><span class="Bold">have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</dd>
<dt>·</dt>
<dd><span class="Bold">currently have or have had certain cancers</span></dd>
<dt> </dt>
<dd>Estrogens may increase the chances of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your healthcare provider about whether you should take CENESTIN.</dd>
<dt>·</dt>
<dd><span class="Bold">had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></span></dd>
<dt>·</dt>
<dd><span class="Bold">currently have or have had blood clots</span></dd>
<dt>·</dt>
<dd><span class="Bold">currently have or have had liver problems</span></dd>
<dt>·</dt>
<dd><span class="Bold">have been diagnosed with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder</span></dd>
<dt>·</dt>
<dd>
<span class="Bold">are allergic to CENESTIN or any of its ingredients<br></span>See the list of ingredients in CENESTIN at the end of this leaflet.</dd>
<dt>·</dt>
<dd><span class="Bold">think you may be pregnant</span></dd>
<dt> </dt>
<dd>CENESTIN is not for pregnant women. If you think you may be pregnant, you should have a pregnancy test and know the results. Do not take CENESTIN if the test is positive and talk to your healthcare provider.</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before I take CENESTIN?</span></p>
<p><span class="Bold">Before you take CENESTIN, tell your healthcare provider if you:</span></p>
<dl>
<dt>·</dt>
<dd><span class="Bold">have any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</dd>
<dt>·</dt>
<dd><span class="Bold">have any other medical conditions</span></dd>
<dt> </dt>
<dd>Your healthcare provider may need to check you more carefully if you have certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span> and tongue), or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.</dd>
<dt>·</dt>
<dd><span class="Bold">are going to have surgery or will be on bed rest </span></dd>
<dt> </dt>
<dd>Your healthcare provider will let you know if you need to stop taking CENESTIN. </dd>
<dt>·</dt>
<dd><span class="Bold">are breastfeeding</span></dd>
<dt> </dt>
<dd>The hormones in CENESTIN can pass into your breast milk.<span class="Bold"></span>
</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may affect how CENESTIN works. CENESTIN may also affect how your other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take CENESTIN?</span></p>
<dl>
<dt>•</dt>
<dd>Take CENESTIN exactly as your healthcare provider tells you to take it.</dd>
<dt>•</dt>
<dd>Take 1 CENESTIN tablet at the same time each day. </dd>
<dt>•</dt>
<dd>You and your healthcare provider should talk regularly (every 3 to 6 months) about the dose you are taking and whether you still need treatment with CENESTIN.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of CENESTIN?</span></p>
<p><span class="Bold">Side effects are grouped by how serious they are and how often they happen when you are treated.</span></p>
<p><span class="Bold">Serious, but less common side effects include:</span></p>
<dl>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> </dd>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></dd>
<dt>·</dt>
<dd>blood clots </dd>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> </dd>
<dt>·</dt>
<dd>breast cancer</dd>
<dt>·</dt>
<dd>cancer of the lining of the uterus (womb)</dd>
<dt>·</dt>
<dd>cancer of the ovary</dd>
<dt>·</dt>
<dd>high blood pressure</dd>
<dt>·</dt>
<dd>high blood sugar</dd>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> </dd>
<dt>·</dt>
<dd>liver problems</dd>
<dt>·</dt>
<dd>changes in your thyroid hormone levels</dd>
<dt>·</dt>
<dd>enlargement of benign tumors of the uterus (“fibroids?)</dd>
</dl>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following warning signs, or any other unusual symptoms that concern you:</span></p>
<dl>
<dt>·</dt>
<dd>new <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> </dd>
<dt>·</dt>
<dd>unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></dd>
<dt>·</dt>
<dd>changes in vision or speech </dd>
<dt>·</dt>
<dd>sudden new severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></dd>
<dt>·</dt>
<dd>severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span> in your chest or legs with or without <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> </dd>
</dl>
<p><span class="Bold">Less serious, but common side effects include:</span></p>
<dl>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </dd>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>·</dt>
<dd>irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting</dd>
<dt>·</dt>
<dd>stomach or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span></dd>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></dd>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span></dd>
<dt>·</dt>
<dd>vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span></dd>
</dl>
<p>These are not all the possible side effects of CENESTIN. For more information, ask your healthcare provider or pharmacist.  Tell your healthcare provider if you have any side effects that bother you or does not go away. </p>
<p>You may report side effects to Teva Branded Pharmaceutical Products at 1-888-483-8279 or to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">What can I do to lower my chances of a serious side effect with CENESTIN?</span></p>
<dl>
<dt>·</dt>
<dd>Talk with your healthcare provider regularly about whether you should continue taking CENESTIN.</dd>
<dt>·</dt>
<dd>If you have a uterus, talk to your healthcare provider about whether the addition of a progestin is right for you.</dd>
<dt>•</dt>
<dd>The addition of a progestin is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb).  </dd>
<dt> </dt>
<dd>See you healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while taking CENESTIN.</dd>
<dt>·</dt>
<dd>Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else. </dd>
<dt> </dt>
<dd>If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram, you may need to have breast exams more often.</dd>
<dt>·</dt>
<dd>If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have higher chances of getting heart disease. </dd>
<dt> </dt>
<dd>Ask your healthcare provider for ways to lower your chances of getting heart disease.</dd>
</dl>
<p><span class="Bold">How should I store CENESTIN?</span></p>
<dl>
<dt>•</dt>
<dd>Store CENESTIN at room temperature between 68°F to 77°F (20°C to 25°C). </dd>
</dl>
<p><span class="Bold">Keep CENESTIN and all other medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about safe and effective use of CENESTIN.</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take CENESTIN for conditions for which it was not prescribed. Do not give CENESTIN to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet provides a summary of the most important information about CENESTIN. If you would like more information, talk with your healthcare provider or pharmacist. You can ask your healthcare provider or pharmacist for information about CENESTIN that is written for health professionals. </p>
<p><span class="Bold">What are the ingredients in CENESTIN?</span></p>
<p><span class="Bold">Active Ingredient: </span>synthetic conjugated estrogens, A</p>
<p><span class="Bold">Inactive Ingredients: </span>ethylcellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80 (except 0.45 mg tablets), pregelatinized starch, titanium dioxide, and triethyl citrate.</p>
<dl>
<dt>·</dt>
<dd>0.3 mg tablets also contain FD&amp;C Blue No. 2 aluminum lake and D&amp;C Yellow No. 10 aluminum lake.</dd>
<dt>·</dt>
<dd>0.45 mg tablets also contain FD&amp;C Yellow No. 6/Sunset Yellow FCF lake.</dd>
<dt>·</dt>
<dd>0.625 mg tablets also contain FD&amp;C Red No. 40 aluminum lake.</dd>
<dt>·</dt>
<dd>0.9 mg tablets do not contain any additional color additives.</dd>
<dt>·</dt>
<dd>1.25 mg tablets also contain FD&amp;C Blue No. 2 aluminum lake.</dd>
</dl>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured By:</p>
<p>Teva Women’s Health, Inc.</p>
<p>Subsidiary of Teva Pharmaceuticals USA, Inc.</p>
<p>North Wales, PA 19454</p>
<p>Revised: 03/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_2956bf37-afd5-4e65-aa57-7d9fdb53d143"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel </h1>
<div class="Figure">
<a name="id1168666745"></a><img alt="Cenestin® (synthetic conjugated estrogens, A) Tablets 0.3 mg, 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-12.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ed87db78-d51a-4935-9495-155fa72f980e"></a><a name="section-18.1"></a><p></p>
<h2>Cenestin® (synthetic conjugated estrogens, A) Tablets 0.3 mg, 100s Label Text </h2>
<p class="First"><span class="Bold">NDC</span> 51285-<span class="Bold">441</span>-02</p>
<p><span class="Bold">Cenestin®</span></p>
<p><span class="Bold">(synthetic conjugated</span></p>
<p><span class="Bold">estrogens, A)</span> Tablets</p>
<p><span class="Bold">0.3 mg</span></p>
<p>PHARMACIST:  Dispense the Package Insert</p>
<p>provided separately to each patient.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
<p>TEVA WOMEN’S HEALTH</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_56eb00d1-f5dc-4cd8-bbe8-3f4b4b5c0544"></a><a name="section-19"></a><p></p>
<h1>Package/Label Display Panel </h1>
<div class="Figure">
<a name="id1168671763"></a><img alt="Cenestin® (synthetic conjugated estrogens, A) Tablets 0.45 mg, 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-13.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_264acb6c-9922-42a2-8e94-aa5d048ee51b"></a><a name="section-19.1"></a><p></p>
<h2>Cenestin® (synthetic conjugated estrogens, A) Tablets 0.45 mg, 100s Label Text </h2>
<p class="First"><span class="Bold">NDC</span> 51285-<span class="Bold">446</span>-02</p>
<p><span class="Bold">Cenestin®</span></p>
<p><span class="Bold">(synthetic conjugated</span></p>
<p><span class="Bold">estrogens, A)</span> Tablets</p>
<p><span class="Bold">0.45 mg</span></p>
<p>PHARMACIST:  Dispense the Package Insert</p>
<p>provided separately to each patient.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
<p>TEVA WOMEN’S HEALTH</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_6e4b8bd7-2546-433c-849d-f1173d70be04"></a><a name="section-20"></a><p></p>
<h1>Package/Label Display Panel </h1>
<div class="Figure">
<a name="id1168671765"></a><img alt="Cenestin® (synthetic conjugated estrogens, A) Tablets 0.625 mg, 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-14.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_368bedcc-d75c-4384-8c22-294020f68ffe"></a><a name="section-20.1"></a><p></p>
<h2>Cenestin® (synthetic conjugated estrogens, A) Tablets 0.625 mg, 100s Label Text </h2>
<p class="First"><span class="Bold">NDC</span> 51285-<span class="Bold">442</span>-02</p>
<p><span class="Bold">Cenestin®</span></p>
<p><span class="Bold">(synthetic conjugated</span></p>
<p><span class="Bold">estrogens, A)</span> Tablets</p>
<p><span class="Bold">0.625 mg</span></p>
<p>PHARMACIST:  Dispense the Package Insert</p>
<p>provided separately to each patient.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
<p>TEVA WOMEN’S HEALTH</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_8b2b4a25-c07c-4cbe-9356-9b0aa0d81366"></a><a name="section-21"></a><p></p>
<h1>Package/Label Display Panel </h1>
<div class="Figure">
<a name="id1168671767"></a><img alt="Cenestin® (synthetic conjugated estrogens, A) Tablets 0.9 mg, 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-15.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1a8a494e-c83d-46eb-b7bb-553d27f6af4a"></a><a name="section-21.1"></a><p></p>
<h2>Cenestin® (synthetic conjugated estrogens, A) Tablets 0.9 mg, 100s Label Text </h2>
<p class="First"><span class="Bold">NDC</span> 51285-<span class="Bold">443</span>-02</p>
<p><span class="Bold">Cenestin®</span></p>
<p><span class="Bold">(synthetic conjugated</span></p>
<p><span class="Bold">estrogens, A)</span> Tablets</p>
<p><span class="Bold">0.9 mg</span></p>
<p>PHARMACIST:  Dispense the Package Insert</p>
<p>provided separately to each patient.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
<p>TEVA WOMEN’S HEALTH</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_df791cc5-24d8-47c9-9044-c53f6ec7390b"></a><a name="section-22"></a><p></p>
<h1>Package/Label Display Panel </h1>
<div class="Figure">
<a name="id1168671769"></a><img alt="Cenestin® (synthetic conjugated estrogens, A) Tablets 1.25 mg, 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=410f9433-98ed-4c3f-abb1-2386296d2f72&amp;name=image-16.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a2285d18-bf48-427f-8c78-b94e6f411bbd"></a><a name="section-22.1"></a><p></p>
<h2>Cenestin® (synthetic conjugated estrogens, A) Tablets 1.25 mg, 100s Label Text </h2>
<p class="First"><span class="Bold">NDC</span> 51285-<span class="Bold">444</span>-02</p>
<p><span class="Bold">Cenestin®</span></p>
<p><span class="Bold">(synthetic conjugated</span></p>
<p><span class="Bold">estrogens, A)</span> Tablets</p>
<p><span class="Bold">1.25 mg</span></p>
<p>PHARMACIST:  Dispense the Package Insert</p>
<p>provided separately to each patient.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
<p>TEVA WOMEN’S HEALTH</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CENESTIN 		
					</strong><br><span class="contentTableReg">synthetic conjugated estrogens, a tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51285-441</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, CONJUGATED SYNTHETIC A</strong> (ESTROGENS, CONJUGATED SYNTHETIC A) </td>
<td class="formItem">ESTROGENS, CONJUGATED SYNTHETIC A</td>
<td class="formItem">0.3 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2208 (4000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">dp;41</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51285-441-02</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">08/05/2002</td>
<td class="formItem">04/30/2016</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020992</td>
<td class="formItem">08/05/2002</td>
<td class="formItem">04/30/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CENESTIN 		
					</strong><br><span class="contentTableReg">synthetic conjugated estrogens, a tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51285-446</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, CONJUGATED SYNTHETIC A</strong> (ESTROGENS, CONJUGATED SYNTHETIC A) </td>
<td class="formItem">ESTROGENS, CONJUGATED SYNTHETIC A</td>
<td class="formItem">0.45 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2208 (4000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">dp;46</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51285-446-02</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">04/01/2004</td>
<td class="formItem">04/30/2015</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020992</td>
<td class="formItem">04/01/2004</td>
<td class="formItem">04/30/2015</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CENESTIN 		
					</strong><br><span class="contentTableReg">synthetic conjugated estrogens, a tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51285-442</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, CONJUGATED SYNTHETIC A</strong> (ESTROGENS, CONJUGATED SYNTHETIC A) </td>
<td class="formItem">ESTROGENS, CONJUGATED SYNTHETIC A</td>
<td class="formItem">0.625 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2208 (4000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">dp;42</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51285-442-02</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">05/12/1999</td>
<td class="formItem">04/30/2016</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020992</td>
<td class="formItem">05/12/1999</td>
<td class="formItem">04/30/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CENESTIN 		
					</strong><br><span class="contentTableReg">synthetic conjugated estrogens, a tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51285-443</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, CONJUGATED SYNTHETIC A</strong> (ESTROGENS, CONJUGATED SYNTHETIC A) </td>
<td class="formItem">ESTROGENS, CONJUGATED SYNTHETIC A</td>
<td class="formItem">0.9 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2208 (4000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">dp;43</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51285-443-02</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">05/12/1999</td>
<td class="formItem">04/30/2016</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020992</td>
<td class="formItem">05/12/1999</td>
<td class="formItem">04/30/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CENESTIN 		
					</strong><br><span class="contentTableReg">synthetic conjugated estrogens, a tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51285-444</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, CONJUGATED SYNTHETIC A</strong> (ESTROGENS, CONJUGATED SYNTHETIC A) </td>
<td class="formItem">ESTROGENS, CONJUGATED SYNTHETIC A</td>
<td class="formItem">1.25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2208 (4000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">dp;44</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51285-444-02</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">03/20/2000</td>
<td class="formItem">04/30/2016</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020992</td>
<td class="formItem">03/20/2000</td>
<td class="formItem">04/30/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Teva Women's Health, Inc.
							(017038951)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>64f3a4cd-512e-414a-8d9b-df45c80a14f6</div>
<div>Set id: 410f9433-98ed-4c3f-abb1-2386296d2f72</div>
<div>Version: 5</div>
<div>Effective Time: 20150818</div>
</div>
</div> <div class="DistributorName">Teva Women's Health, Inc.</div></p>
</body></html>
